Today's After-Hours Movers:Sarepta Therapeutics (NASDAQ: SRPT) 26.7% HIGHER; announced that the FDA has requested that Sarepta provide dystrophin data, as ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

BMO Capital Remains Sidelined on Casey's General Stores (CASY) Following 4Q June 8, 2016 8:44 AM Jefferies Raises Price Target on Casey's General Stores (CASY) to $113 Following EPS Miss June 8, 2016 8:12 AM Oppenheimer Cuts Price Target on Alexion Pharma (ALXN) Following Data Release June 7, 2016 9:46 AM UBS Remains Neutral on Xactly Corporation (XTLY) Following 1Q Beat and Raise June 7, 2016 9:25 AM Jefferies Raises Price Target on United Natural Foods (UNFI) Following EPS Beat June 7, 2016 8:53 AM Jefferies Remains Sidelined on Casey's General Stores (CASY) Following Mixed 4Q June 7, 2016 8:46 AM Jefferies Remains Bullish as DSW, Inc's (DSW) CFO Announces Resignation June 7, 2016 8:36 AM FBR Capital Remains Sidelined on Enova International (ENVA) Following New CFPB Payday Lending Rules June 7, 2016 8:16 AM Needham & Company Remains Bullish on Sigma Designs (SIGM) Following 1Q Earnings Report June 7, 2016 8:04 AM Baird Remains Bullish on Sigma Designs (SIGM) Following 1Q Beat June 7, 2016 7:20 AM BMO Capital Raises Price Target on United Natural Foods (UNFI) Following 3Q June 7, 2016 7:05 AM Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - OppenheimerJune 7, 2016 6:49 AM Needham & Company Raises Price Target on Xactly Corporation (XTLY) Following Solid 1Q Results June 7, 2016 6:42 AM